Literature DB >> 21959283

Targeting MYC? You BET.

Gemma K Alderton.   

Abstract

Year:  2011        PMID： 21959283     DOI： 10.1038/nrd3569

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582
  1 in total
  2 in total

1.  MCM5 as a target of BET inhibitors in thyroid cancer cells.

Authors:  Catia Mio; Elisa Lavarone; Ketty Conzatti; Federica Baldan; Barbara Toffoletto; Cinzia Puppin; Sebastiano Filetti; Cosimo Durante; Diego Russo; Arturo Orlacchio; Antonio Di Cristofano; Carla Di Loreto; Giuseppe Damante
Journal:  Endocr Relat Cancer       Date:  2016-02-24       Impact factor: 5.678

2.  Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification.

Authors:  Rosalia Fernandez-Alonso; Lindsay Davidson; Jens Hukelmann; Michael Zengerle; Alan R Prescott; Angus Lamond; Alessio Ciulli; Gopal P Sapkota; Greg M Findlay
Journal:  EMBO Rep       Date:  2017-06-06       Impact factor: 8.807
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.